FDA approves lisocabtagene maraleucel (Breyanzi) for relapsed or refractory mantle cell lymphoma (MCL) after two prior lines of therapy

On May 30, 2024, the Food and Drug Administration (FDA) approved lisocabtagene maraleucel - Breyanzi for adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least two prior lines of systemic therapy, including a Bruton tyrosine kinase inhibitor (BTKi).

Full prescribing information for Breyanzi will be posted here.

Source